Manuka honey with cycloPower™ ő a novel bioactive complex of manuka honey and α‐cyclodextrin (259.4)

Manuka honey is recognised for its health‐promoting properties and its use in medicine is well documented. However, the actions of Manuka honey are limited by rapid digestion and the inactivation of bioactive components such as methylglyoxal (MG). Cyclodextrins are naturally‐occurring glucose rings that improve stability and bioactivity of products. This study investigates the tolerability and bioactivity of α‐cyclodextrin‐complexed Manuka honey called Manuka Honey with CycloPower™ (MH‐CP).Product tolerability was evaluated in a randomized, double‐blind, ascending dose study. Healthy participants (n=64) consumed 400‐4800mg or placebo for two weeks. MH‐CP was well tolerated. The most common events were headache and temporary mild/ moderate gastrointestinal disturbances (diarrhea, nausea). The rate of adverse events (AEs) was not dose‐related and most AEs resolved within 48 hours. A further study assessed the glycemic index (GI) of MH‐CP and revealed that the GI was significantly reduced (GI=18 vs 55) compared with uncomplexed Manuka honey. In addition, a suite of in vitro analyses indicated that MH‐CP has enhanced antimicrobial efficacy against a range of common gut organisms compared with Manuka honey. This demonstrates that Manuka honey with CycloPower™ is a well‐tolerated product with enhanced bioactive properties.